• Molecular subtypes redefining treatment algorithms in aggressive and indolent lymphomas?
• Should MRD negativity become a standard endpoint in CLL management?
• Next-gen agents BTK I (non-covalent BTKi) in relapsed/refractory CLL.
• Bispecific antibodies: Mosunetuzumab and glofitamab in B-cell lymphomas.
• BCL2 inhibitors: Venetoclax-based regimens in CLL and mantle cell lymphoma.
• What are the sequencing strategies for BTK and BCL2 inhibitors in CLL?
• Comparing bispecifics to CAR-T in terms of efficacy and accessibility?

1. Peri-operatives CH-IO
2. Locally advanced NSCLC, Management approach
3. First-Line Treatment AGA
4. IO duration-biomarker
5. First Line EGFR+, Second Line EGFR +
6. First Line exon20 Ins
7. 1st ALK treatment
8. K-RAS management

Prostate cancer:
• The evolving role of PSMA-targeted radioligand imaging and therapy in prostate cancer
• Feasibility of PARPi as upfront therapy in MCRPC
• ARPI in high risk localized cancer and in biochemical relapse in NMCSPC
• Outcome of triple therapy in MCSPC

Bladder cancer:
• Expansion the role of IO in NMIBC, localized MIBC
• Approach for 1st line in metastatic TCC , roie of biomatrkers, pPRO
• Treatment sequencing in TCC
• Genomic profiling directed treatment and ADCs in TCC

Kidney caner:
• Validity of Adjuvant IO in RCC ,
• Approach to 1st line treatment in ccRCC
• Sequencing of subsequent lines
• Approach to nCCRCC.
• Ole of markers and genomic profile in RCC ( VHL directed treatment)

• Integration of the genomic tests in breast cancer , when and for whom
• Role of new radionuclide based imaging, in breast cancer imaging
• Expanding the role of CDK4/6 in HR+ ve early breast cancer
• New role of oral SERD in HR+ ve breast cancer, pre progression and post progression on CDK4/6i
• Expanding the role of Anti PIK3CA in breast cancer, in first line with CDK4/6 and post CDK4/6i failure
• AKT inhibitor as an acceptable choice post CDK4/6i
• Expanding the role of T-Dxd in perioperative setting in HER2 positive breast cancer (DB-05&DB-11)
• Paradigm change in first line of advanced/metastatic HER2 positive breast cancer
• TKI and how to sequence treatment lines in HER2new positive breast cancer
• Immunotherapy in TNBC what did we achieved so far
• Expanding role of ADCs in TNBC in first and subsequent lines in TNBC
• ADCs in HR+ve breast cancer (Tropics&Tropion breast-02)
• Breast cancer Vaccines
• Topics arise from ESMO 25 and SABCS 25 (evERA Breast Cancer Study, aphinity final results..etc)

• Impact of biomarkers on treatment of ovarian cancer ?
• Stratification for endometrial cancer based on the biomarker and pragmatic implantation in practice?
• How to translate results results of PARP inhibitor trials in maintenance and recurrent ovarian cancer (e.g., ATHENA-MONO, DUO)?
• New antibody-drug conjugates (ADCs) showing promise in platinum-resistant ovarian cancer?
• Stratification for endometrial cancer based on the biomarker and pragmatic implantation in practice?
• Efficacy of combination regimens (IO + anti-angiogenic agents) in first and recurrent endometrial cancer?
• Is there effective treatment in second and subsequent line in endometrial cancer?
• Emerging therapies for clear cell and carcinosarcoma subtypes, which traditionally have poor outcomes?
• Results of integrated IO into frontline therapy for advanced cervical cancer?
• Subsequent treatment in cervical cancer , what do we have?
• Discussion any arising hot topics in ESMO meetings

Colorectal Cancer:
• Colon cancer incidence increase, and shift to younger age, how to decrease it
• Genomic profiling , timing, approach, and requirements
• First line, paradigm shift in era of anti BRAF (Breakwater trial), AntiHER2, Anti RAS (CODEBREAK300)
• Second line, paradigm shift in era of anti BRAF (BIACON TRIAL), AntiHER2 (MOUNTAINEER, HERCLES-A) , Anti RAS (CHRYSTAL1, CODEBREAk101)
• Third Line paradigm Shift in era of anti BRAF, AntiHER2 (DESTINY-CRC01, TRIUMPH), Anti RAS
• Rechallange versus 3rd line treatment and impact of Danish trial of lonsurf and bevacizumab on common practice
• Preoperative chemotherapy role and when
• Preopearative Immunotherapy should we adapt, including possible changes in adjuvant treatment (Atomic trial)
• Metastatectomy how far should we go
• TNT best use and sequencing

Gastric Cancer:
• Does Perioperative immunotherapy, reshape treatment approach in localized gastric and GEJ cancer.
• How IO in advanced setting,improved outcome
• Approach and selecting combination based on Pd-L1 %
• Car-T cell may be a reality in third line in metastaic gastric cancer

HCC:
• Applicable combinations in local treatment approaches.
• How to choose among the available options.

Cholangio-carcinoma:
• Approach to first line treatment
• Considerations regarding treatment approaches for different biliary tract carcinoma sites
• Second line options hopes vs reality

Pancreas:
• Impact of NAPOLI 3 , and POLO trial on practice